SRPT, ACRX ... and FOLD (which still has great potential). And AMBS as a very speculative one but probably with 100-bagger potential until 2016
The Company will seek to gain 'Breakthrough,' 'Fast Track' and/or 'Orphan Drug Designation' status with the FDA where the Company believes the data generated justifies such a designation, potentially significantly reducing the time to market for MANF and/or improving the potential economic outcome for the Company.
The Company believes MANF could address the following very significant market opportunities:
-- Parkinson's disease: $1 billion
-- Traumatic Brain Injury: $200 million
-- Ischemic Heart Disease: $2 billion
-- Diabetes: $2 billion
-- Orphan diseases: $2 billion
BIG TIME, BABY ... get ready for 1$, 5$, 20$, 50$
Sentiment: Strong Buy
Registered on 6 April and already 83 posts on the SRPT board (and not a single message on any other board) ... come on, man. What is your hourly rate? Do you follow a certain KPI? (posts per hour?)
they will pay themselves fat bonuses and leave the stage. mark my post!
nothing is more stupid as to believe, this company will have any future. of course, shorting is also not very intelligent anymore. I believe this to settle around 1,00 and then to be diluted due to cash need. sad but true